Metabolic Assessment | a new paradigm for managing disease risk

Stacks Image 47
Our technology finds differences between metabolite levels in the blood of healthy subjects (gray bars) compared to patients with different diseases (colored bars). We then design tests that identify risks for specific diseases based on these abnormal metabolite levels.

We work with top collaborators around the world to discover and validate our tests, and continue active research programs focused on understanding how these imbalances cause disease.
Chronic diseases such as cancer and Alzheimer's disease develop slowly over many years. A complex interaction between an individual's genetic background and their environment, lifestyle, dietary habits, geographic location, occupation, and many other factors, determine which disease a person might develop.

These interactions exert their effects within the body at the molecular level, without any noticeable symptoms. But they can occur, accumulating over many years.

Eventually, the functions of cells become affected. This leads to compromises in physiological functions and clinically-noticeable outcomes such as tumour growth, onset of dementia, or other symptoms.

Our research has identified several metabolic system imbalances that correlate with the presence of several diseases including
colorectal cancer, pancreatic cancer and Alzheimer's disease. We believe these imbalances begin well before, and play a role in, the development of disease.

Detecting people among the general population with these pre-symptomatic metabolic imbalances is the fundamental concept of our tests. These individuals can then more closely monitor their heath, adopt lifestyle changes to reduct their risk, or could be candidates for pharmacologically correcting the imbalance.

Most people would agree that a disease does not spontaneously appear within the body. For instance, a person does not go to bed completely healthy, only to wake up the next morning with colorectal cancer. Rather, underlying biochemical and cellular changes leading to the disease begin to occur long before.

Our tests are different than conventional screening tests because they do not detect symptoms. By detecting biochemical imbalances, our tests divide the average-risk population into a small group with increased risk and a large group with reduced risk. High-risk subjects can then be proactive in further screening and follow up.